At the end of the latest market close, Altamira Therapeutics Ltd. (CYTO) was valued at $1.60. In that particular session, Stock kicked-off at the price of $1.63 while reaching the peak value of $1.70 and lowest value recorded on the day was $1.53. The stock current value is $1.73.Recently in News on October 14, 2021, Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application. Altamira Therapeutics Ltd. (NASDAQ:CYTO) (“Altamira” or the “Company”), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration (“FDA”) for its Bentrio™ nasal spray for protection against airborne allergens has cleared the Agency’s acceptance review. The application now moves to a substantive review by the FDA. You can read further details here
Altamira Therapeutics Ltd. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $6.2500 on 03/09/21, with the lowest value was $1.5300 for the same time period, recorded on 10/13/21.
Altamira Therapeutics Ltd. (CYTO) full year performance was 55.34%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Altamira Therapeutics Ltd. shares are logging -73.76% during the 52-week period from high price, and 122.06% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.78 and $6.60.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4279153 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Altamira Therapeutics Ltd. (CYTO) recorded performance in the market was -38.93%, having the revenues showcasing -47.02% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 23.09M, as it employees total of 9 workers.
Market experts do have their say about Altamira Therapeutics Ltd. (CYTO)
During the last month, 0 analysts gave the Altamira Therapeutics Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.8944, with a change in the price was noted -1.44. In a similar fashion, Altamira Therapeutics Ltd. posted a movement of -44.58% for the period of last 100 days, recording 839,882 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CYTO is recording 0.03 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Altamira Therapeutics Ltd. (CYTO)
Raw Stochastic average of Altamira Therapeutics Ltd. in the period of last 50 days is set at 15.03%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 25.00%. In the last 20 days, the company’s Stochastic %K was 12.98% and its Stochastic %D was recorded 9.37%.
Bearing in mind the latest performance of Altamira Therapeutics Ltd., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -38.93%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -54.55%, alongside a boost of 55.34% for the period of the last 12 months. The shares -7.51% in the 7-day charts and went up by -31.03% in the period of the last 30 days. Common stock shares were lifted by -47.02% during last recorded quarter.